Sigletic

Package leaflet: Information for the patient

Sigletic, 25 mg, film-coated tablets
Sigletic, 50 mg, film-coated tablets
Sigletic, 100 mg, film-coated tablets
Sitagliptinum
Please read the entire leaflet carefully before taking this medicine, as it contains
important information for the patient.

• Keep this leaflet, as you may need to read it again.
• If you have any questions, consult your doctor or pharmacist.
• This medicine has been prescribed for a specific individual. Do not pass it on to others. It may harm someone else, even if their symptoms are the same.
• If you experience any adverse reactions, including those not listed in this leaflet, inform your doctor or pharmacist. See section 4.

Table of contents

1. What Sigletic is and what it is used for
2. Important information before taking Sigletic
3. How to take Sigletic
4. Possible side effects
5. How to store Sigletic
6. Contents of the pack and other information

1. What Sigletic is and what it is used for

Sigletic contains the active substance sitagliptin, which belongs to a class of medicines called
DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors), which reduce blood glucose levels
in adults with type 2 diabetes.
This medicine helps increase the amount of insulin released after meals and reduces the amount of glucose
produced by the body.
Your doctor has prescribed this medicine to help lower high blood glucose levels caused by
type 2 diabetes. It may be used alone or in combination with other glucose-lowering medicines
(such as insulin, metformin, sulfonylureas, or glitazones) that you may already be taking,
along with diet and exercise regimen.

What is type 2 diabetes?
Type 2 diabetes is a condition in which the body does not produce enough insulin, and the insulin that is produced does not work properly. The body may also produce too much glucose.
When this occurs, sugar (glucose) accumulates in the blood. This can lead to serious health problems, such as heart disease, kidney disease, vision loss, and limb amputations.

2. Important information before using Sigletic

When not to use Sigletic

• if the patient is allergic to sitagliptin or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions
Before starting treatment with Sigletic, discuss this with your doctor or pharmacist.
Cases of pancreatitis have been reported in patients taking Sigletic (see section 4).
If the patient develops skin blisters, this may be a symptom of a disease called bullous pemphigoid. The doctor may advise the patient to stop taking Sigletic.
Inform the doctor if the patient has or has had:

• pancreatic disease (e.g. pancreatitis);
• gallstones, alcohol dependence, or very high levels of triglycerides (a form of fat) in the blood. In such cases, the risk of pancreatitis may be increased (see section 4);
• type 1 diabetes;
• diabetic ketoacidosis (a diabetes complication characterized by high blood sugar levels, rapid weight loss, nausea or vomiting);
• any kidney problems, either currently or in the past;
• allergic reaction to Sigletic (see section 4).

Since this medicine does not act when blood glucose levels are low, it is unlikely to cause excessively low blood sugar levels. However, if this medicine is used together with a sulfonylurea or insulin, low blood sugar (hypoglycaemia) may occur. The doctor may reduce the dose of the sulfonylurea or insulin.
Children and adolescents
Children and adolescents under 18 years of age should not take this medicine.
This medicine is not effective in children and adolescents aged 10 to 17 years. It is not known whether this medicine is safe and effective in children under 10 years of age.
Sigletic and other medicines
Tell your doctor or pharmacist if the patient is taking, has recently taken or might take any other medicines.
In particular, inform the doctor if the patient is taking digoxin (a medicine used to treat heart rhythm disorders and other heart conditions). Blood levels of digoxin should be monitored when Sigletic is taken concomitantly with digoxin.
Pregnancy and breastfeeding
If the patient is pregnant, breastfeeding, suspects she may be pregnant, or is planning to have a baby, she should consult her doctor or pharmacist before using this medicine.
This medicine should not be used during pregnancy.
It is not known whether this medicine passes into human breast milk. This medicine should not be used during breastfeeding or if breastfeeding is planned.
Driving and operating machinery
This medicine has no effect or a negligible effect on the ability to drive and operate machinery. However, when driving and operating machinery, take into account that dizziness and drowsiness have been reported.
Taking this medicine together with medicines called sulfonylureas or with insulin may lead to hypoglycaemia, which in turn may affect the ability to drive and operate machinery or work without secure foot support.
Sigletic contains sodium
Sigletic contains less than 1 mmol of sodium (23 mg) per dose, i.e. the medicine is considered "sodium-free".

3. How to take Sigletic

This medicine should always be taken exactly as directed by your doctor. If you have any doubts, consult your doctor or pharmacist.

The usual recommended dose is:

• one 100 mg coated tablet;
• once daily;
• taken orally.

If the patient has impaired kidney function, the doctor may recommend a lower dose of Sigletic (e.g. 25 mg or 50 mg).
This medicine can be taken with food and drinks or independently of meals and beverages.
Your doctor may recommend taking this medicine alone or in combination with other medicines that reduce blood sugar levels.
Diet and physical exercise help the body to use blood sugar more effectively.
While taking Sigletic, it is important to follow the diet and physical activity regimen recommended by your doctor.
The 50 mg and 100 mg tablets of Sigletic can be divided into two equal doses.
If your doctor has prescribed half a 50 mg tablet or half a 100 mg tablet, please follow the instructions below for splitting Sigletic tablets.

Instructions for splitting the tablet

1. Place the tablet on a flat, hard surface (e.g. a table or countertop), with the side bearing the break line facing upwards.
2. Break the tablet along the vertical line by pressing down with the index fingers of both hands against the surface, as shown in Figures 1 and 2.

Figures 1 and 2: Splitting a Sigletic tablet into two equal doses.

Taking more Sigletic than prescribed
If you take more Sigletic than prescribed, contact your doctor immediately.

Missing a dose of Sigletic
If you miss a dose, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose.

Stopping Sigletic
To maintain control of your blood sugar levels, continue taking this medicine for as long as your doctor recommends. Do not stop taking this medicine without first consulting your doctor.

If you have any further questions about the use of this medicine, consult your doctor or pharmacist.

4. Possible adverse reactions

Like all medicines, this medicine can cause adverse reactions, although not everybody will experience them.
You should DISCONTINUE the use of Sigletic and contact your doctor immediately if any of the following severe adverse reactions occur:

• Severe and persistent abdominal pain (in the stomach area), possibly radiating to the back, with or without nausea and vomiting – these may be symptoms of pancreatitis.

In case of a severe allergic reaction (frequency unknown), including rash, urticaria, skin blisters or skin peeling, and swelling of the face, lips, tongue or throat, which may cause difficulty in breathing or swallowing, you must stop taking the medicine and contact your doctor immediately. Your doctor may prescribe medication to treat the allergic reaction and another medicine to treat diabetes.

In some patients, the following adverse reactions occurred when sitagliptin was added to metformin:

Frequent (may occur in up to 1 in 10 people): low blood sugar levels, nausea, bloating, vomiting.

Uncommon (may occur in up to 1 in 100 people): stomach pain, diarrhoea, constipation, drowsiness.

Some patients experienced various gastrointestinal symptoms after starting treatment with sitagliptin in combination with metformin (frequent).

In some patients receiving sitagliptin in combination with a sulfonylurea and metformin, the following adverse reactions occurred:

Very common (may occur in more than 1 in 10 people): low blood sugar levels.

Frequent: constipation.

In some patients receiving sitagliptin with pioglitazone, the following adverse reactions occurred:

Frequent: bloating, swelling of hands or feet.

In some patients receiving sitagliptin in combination with pioglitazone and metformin, the following adverse reactions occurred:

Frequent: swelling of hands or feet.

In some patients receiving sitagliptin in combination with insulin (with or without metformin), the following adverse reactions occurred:

Frequent: influenza.

Uncommon: dry mouth.

In some patients receiving sitagliptin alone and/or with other antidiabetic medicines in clinical trials or during post-marketing use, the following adverse reactions occurred:

Frequent: low blood sugar levels, headache, upper respiratory tract infections, stuffy or runny nose and sore throat, bone and joint inflammation, pain in arm or leg.

Uncommon: dizziness, constipation, itching.

Rare: decreased platelet count.

Frequency not known: kidney disorders (sometimes requiring dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blistering).

Reporting of adverse reactions

If any adverse reactions occur, including any not listed in this leaflet, inform your doctor, pharmacist, or nurse. Adverse reactions can be reported directly to the Department of Monitoring Adverse Drug Reactions, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Al. Jerozolimskie 181C
02-222 Warsaw
Tel.: + 48 22 49 21 301
Fax: + 48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Adverse reactions can also be reported to the marketing authorisation holder.

Reporting adverse reactions helps provide more information on the safety of the medicine.

5. How to store the medicine Sigletic

There are no special requirements for storing this medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the blister and carton after:
"EXP". The expiry date refers to the last day of the stated month.
The marking on the packaging after the abbreviation "EXP" indicates the expiry date, and after the abbreviation "Lot/LOT" indicates the batch number.
Medicines must not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer in use. Such measures will help protect the environment.

6. Contents of the pack and other information

What the medicine Sigletic contains

• The active substance is sitagliptin. Each coated tablet contains sitagliptin hydrochloride monohydrate, corresponding to 25 mg, 50 mg or 100 mg of sitagliptin, respectively.
• Other ingredients are: Tablet core: microcrystalline cellulose, calcium hydrogen phosphate, sodium carboxymethyl starch (type A), colloidal anhydrous silica, sodium stearyl fumarate. Tablet coating: polyvinyl alcohol, macrogol 3350, talc, titanium dioxide (E 171), yellow iron oxide (E 172), red iron oxide (E 172).

What Sigletic looks like and contents of the pack
Sigletic 25 mg: light pink, round, biconvex coated tablet; tablet diameter 5.9–6.3 mm.
Sigletic 50 mg: light orange, round, biconvex coated tablet with a score line on one side and engraved "50" on the other; tablet diameter 7.9–8.3 mm. The tablet can be divided into equal doses.
Sigletic 100 mg: light brown, round, biconvex coated tablet with a score line on one side and engraved "100" on the other; tablet diameter 9.9–10.4 mm. The tablet can be divided into equal doses.
Packs: PVC/PVDC/Aluminium blisters in cardboard boxes. Pack sizes: 14, 28, 30, 56, 84, 90, 98 coated tablets.
Not all pack sizes may be marketed.

Marketing Authorisation Holder
Zakłady Farmaceutyczne POLPHARMA S.A.
ul. Pelplińska 19, 83-200 Starogard Gdański
tel. +48 22 364 61 01

Manufacturer
Zakłady Farmaceutyczne Polpharma S.A.
Production Site in Nowa Dęba
ul. Metalowca 2
39-460 Nowa Dęba
Zakłady Farmaceutyczne POLPHARMA S.A.
ul. Pelplińska 19, 83-200 Starogard Gdański

This medicine is authorised in the European Economic Area countries under the following names:
Bulgaria - Cиглетик 25 mg, 50 mg, 100 mg филмирани таблетки
Czech Republic - Sitagliptin Polpharma 100 mg potahované tablety
Lithuania - Sigletic 25 mg, 50 mg, 100 mg plėvele dengtos tabletės
Latvia - Sigletic 25 mg, 50 mg, 100 mg apvalkotās tabletes
Poland - Sigletic, 25 mg, 50 mg, 100 mg tabletki powlekane